查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1356823

癌症檢測篩檢市場報告：至2030年的趨勢、預測與競爭分析

Cancer Testing Screening Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

癌症檢測及篩檢趨勢及預測

預計到2030年，全球癌症檢測篩檢市場將達到 2,142 億美元，2024年至2030年年複合成長率為 5.1%。該市場的主要促進因素是癌症患者的盛行率上升，對準確診斷工具和早期檢測方法的需求不斷成長以及對液體活體組織切片的日益偏好。全球癌症檢測篩檢市場的未來前景廣闊，在醫院、診所、診斷中心和研究機構都有應用機會。

癌症測試篩檢市場洞察

Lucintel 預測，由於其對癌症的診斷準確性較高，切片檢查預計將在預測期內實現最高成長。

醫院預計在預測期內將出現最高的成長，因為由於現有基礎設施的便利性和醫療專業人員的存在，患者越來越喜歡這些設施進行治療。

隨著前列腺癌和肺癌患者數量持續增加，預計北美地區在預測期內將出現最高成長。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.哪個細分市場將以更快的速度成長？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些，由於材料或產品替代導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球癌症檢測篩檢市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球癌症檢測和篩檢市場趨勢（2018-2023）和預測（2024-2030）
  • 依技術分類的全球癌症檢測篩檢市場
    • 成像
    • 切片檢查
    • 基因組和分子測試
    • 下一代定序
    • RT-PCR
    • 微陣列
    • 生物標記測試
    • 其他
  • 按癌症類型分類的全球癌症檢測篩檢市場
    • 呼吸系統癌症
    • 白血病
    • 骨髓瘤和淋巴瘤
    • 皮膚癌
    • 腹部/消化器官系統癌症
    • 泌尿器官系統癌症
    • 內分泌癌
    • 乳癌
    • 其他
  • 全球癌症檢測篩檢市場（依應用）
    • 醫院
    • 診所
    • 診斷中心
    • 調查機構
    • 其他
  • 全球癌症檢測篩檢市場（依最終用途）
    • 病人
    • 醫療服務提供方
    • 診斷實驗室
    • 調查機構
    • 製藥公司

第4章 2018-2030年市場趨勢及預測分析（依地區）

  • 全球癌症檢測篩檢市場（依地區）
  • 北美癌症檢測篩檢市場
  • 歐洲癌症檢測篩檢市場
  • 亞太地區癌症檢測篩檢市場
  • 其他區域癌症檢測和篩檢市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球癌症檢測篩檢市場成長機會（依技術）
    • 全球癌症檢測篩檢市場成長機會（按癌症類型）
    • 全球癌症檢測篩檢市場成長機會（依應用）
    • 全球癌症檢測篩檢市場成長機會（依最終用途）
    • 全球癌症檢測篩檢市場成長機會（依地區）
  • 全球癌症檢測篩檢市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球癌症檢測和篩檢市場的能力
    • 全球癌症檢測篩檢市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • DiaSorin
  • Immunodiagnostic Systems
  • Epigenomics
  • Quest Diagnostics
  • F. Hoffmann-La Roche
  • VolitionRX
  • Abbott Laboratories
  • QIAGEN
  • Siemens Healthineers
簡介目錄

Cancer Testing Screening Trends and Forecast

The future of the global cancer testing screening market looks promising with opportunities in the hospital, clinic, diagnostic center, and research institute applications. The global cancer testing screening market is expected to reach an estimated $214.2 billion by 2030 with a CAGR of 5.1% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer cases, growing need for accurate diagnostic tools and early detection methods, and increasing preference for liquid biopsy.

A more than 150-page report is developed to help in your business decisions.

Cancer Testing Screening by Segment

The study includes a forecast for the global cancer testing screening by technique, cancer type, application, end use, and region.

Cancer Testing Screening Market by Technique [Shipment Analysis by Value from 2018 to 2030]:

  • Imaging
  • Biopsy
  • Genomic and Molecular Tests
  • Next Generation Sequencing
  • RT-PCR
  • Microarrays
  • Biomarker Testing
  • Others

Cancer Testing Screening Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Respiratory System Cancer
  • Leukemia
  • Myeloma and Lymphoma
  • Skin Cancer
  • Abdominal/Digestive System Cancer
  • Urinary System Cancer
  • Endocrine System Cancer
  • Breast Cancer
  • Others

Cancer Testing Screening Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Research Institutes
  • Others

Cancer Testing Screening Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Patients
  • Healthcare Providers
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical Companies

Cancer Testing Screening Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Testing Screening Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer testing screening companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer testing screening companies profiled in this report include-

  • Diasorin
  • Immunodiagnostic Systems
  • Epigenomics
  • Quest Diagnostics
  • F. Hoffmann-La Roche
  • VolitionRX
  • Abbott Laboratories
  • QIAGEN
  • Siemens Healthineers

Cancer Testing Screening Market Insights

Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its great accuracy in the diagnosis of cancer.

Hospital is expected to witness highest growth over the forecast perioddue to rising patients preference for this facility for their treatment given to the availibility of well established infrastructure and presence of medical expertise.

North America is expected to witness highest growth over the forecast period due to constant increase in instances of prostate and lung cancer cases in the region.

Features of the Global Cancer Testing Screening Market

Market Size Estimates: Cancer testing screening market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer testing screening market by various segments, such as by technique, cancer type, application, end use and region in terms of($B).

Regional Analysis: Cancer testing screening market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different techniques, cancer types, applications, end uses, and region.s for the cancer testing screening market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer testing screening market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the cancer testing screening market size?

Answer: The global cancer testing screening market is expected to reach an estimated $214.2 billion by 2030.

Q.2. What is the growth forecast for cancer testing screening market?

Answer: The global cancer testing screening market is expected to grow with a CAGR of 5.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the cancer testing screening market?

Answer: The major drivers for this market are rising prevalence of cancer cases, growing need for accurate diagnostic tools and early detection methods, and increasing preference for liquid biopsy.

Q.4. What are the major segments for cancer testing screening market?

Answer: The future of the cancer testing screening market looks promising with opportunities in the hospital, clinic, diagnostic center, and research institute applications.

Q.5. Who are the key cancer testing screening market companies?

Answer: Some of the key cancer testing screening companies are as follows:

  • DiaSorin
  • Immunodiagnostic Systems
  • Epigenomics
  • Quest Diagnostics
  • F. Hoffmann-La Roche
  • VolitionRX
  • Abbott Laboratories
  • QIAGEN
  • Siemens Healthineers

Q.6. Which cancer testing screening market segment will be the largest in future?

Answer: Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its great accuracy in the diagnosis of cancer.

Q.7. In cancer testing screening market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to constant increase in instances of prostate and lung cancer cases in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer testing screening market by technique (imaging, biopsy, genomic and molecular tests, next generation sequencing, RT-PCR, microarrays, biomarker testing, and others), cancer type (respiratory system cancer, leukemia, myeloma and lymphoma, skin cancer, abdominal/digestive system cancer, urinary system cancer, endocrine system cancer, breast cancer, and others), application (hospitals, clinics, diagnostic centers, research institutes, and others), end use (patients, healthcare providers, diagnostic laboratories, research institutes, and pharmaceutical companies), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Testing Screening Market: Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Testing Screening Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Testing Screening Market by Technique
    • 3.3.1: Imaging
    • 3.3.2: Biopsy
    • 3.3.3: Genomic and Molecular Tests
    • 3.3.4: Next Generation Sequencing
    • 3.3.5: RT-PCR
    • 3.3.6: Microarrays
    • 3.3.7: Biomarker Testing
    • 3.3.8: Others
  • 3.4: Global Cancer Testing Screening Market by Cancer Type
    • 3.4.1: Respiratory System Cancer
    • 3.4.2: Leukemia
    • 3.4.3: Myeloma and Lymphoma
    • 3.4.4: Skin Cancer
    • 3.4.5: Abdominal/Digestive System Cancer
    • 3.4.6: Urinary System Cancer
    • 3.4.7: Endocrine System Cancer
    • 3.4.8: Breast Cancer
    • 3.4.9: Others
  • 3.5: Global Cancer Testing Screening Market by Application
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: Diagnostic Centers
    • 3.5.4: Research Institutes
    • 3.5.5: Others
  • 3.6: Global Cancer Testing Screening Market by End Use
    • 3.6.1: Patients
    • 3.6.2: Healthcare Providers
    • 3.6.3: Diagnostic Laboratories
    • 3.6.4: Research Institutes
    • 3.6.5: Pharmaceutical Companies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Testing Screening Market by Region
  • 4.2: North American Cancer Testing Screening Market
    • 4.2.2: North American Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others
  • 4.3: European Cancer Testing Screening Market
    • 4.3.1: European Cancer Testing Screening Market by Technique: Imaging, Biopsy, Genomic and Molecular Tests, Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others
    • 4.3.2: European Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others
  • 4.4: APAC Cancer Testing Screening Market
    • 4.4.1: APAC Cancer Testing Screening Market by Technique: Imaging, Biopsy, Genomic and Molecular Tests, Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others
    • 4.4.2: APAC Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others
  • 4.5: ROW Cancer Testing Screening Market
    • 4.5.1: ROW Cancer Testing Screening Market by Technique: Imaging, Biopsy, Genomic and Molecular Tests, Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others
    • 4.5.2: ROW Cancer Testing Screening Market by Application: Hospitals, Clinics, Diagnostic Centers, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Testing Screening Market by Technique
    • 6.1.2: Growth Opportunities for the Global Cancer Testing Screening Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Cancer Testing Screening Market by Application
    • 6.1.4: Growth Opportunities for the Global Cancer Testing Screening Market by End Use
    • 6.1.5: Growth Opportunities for the Global Cancer Testing Screening Market by Region
  • 6.2: Emerging Trends in the Global Cancer Testing Screening Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Testing Screening Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Testing Screening Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: DiaSorin
  • 7.2: Immunodiagnostic Systems
  • 7.3: Epigenomics
  • 7.4: Quest Diagnostics
  • 7.5: F. Hoffmann-La Roche
  • 7.6: VolitionRX
  • 7.7: Abbott Laboratories
  • 7.8: QIAGEN
  • 7.9: Siemens Healthineers